123 Main Street, New York, NY 10001

Top Navigation with Mega Menu

Co-Dx™ awarded $1.2M from RADx program

Funding will target upper respiratory panel development.

The U.S. National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Tech program has awarded Co-Dx™ $1.2 million to complete the development of its upper respiratory panel.

The multiplex test for influenza A/B, COVID-19, and respiratory syncytial virus runs on the firm’s Co-Dx PCR Home™ Testing Platform. Co-Dx will use the RADx funding to finish the assay’s development and prepare for clinical trials.

Read the article here: